Companies / Japan
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Regulatory Climate Improves
March 2007 | Business Environment OutlookSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
BMI has reinforced its favourable assessment of Japan's regulatory environment after the country's Pharmaceuticals and Medical Devices Agency (PMDA) delineated a biosimilar approval pathway and promised to accelerate the time it takes to approve a new drug. In our Q207 Business Environment Rankings, we will continue to score Japan as nine for regulatory barriers as the country still has some way to go before it possess the most efficient, progressive and transparent monitoring system for pharmaceuticals in the Asia Pacific